Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
T2 Biosystems, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
TTOO
Nasdaq
2836
www.t2biosystems.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for T2 Biosystems, Inc.
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
- Jan 7th, 2025 2:00 pm
T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor
- Dec 18th, 2024 2:00 pm
T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally
- Dec 17th, 2024 2:00 pm
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
- Dec 16th, 2024 2:00 pm
T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens
- Dec 9th, 2024 2:00 pm
T2 Biosystems Inc (TTOO) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ...
- Nov 15th, 2024 7:15 am
T2 Biosystems: Q3 Earnings Snapshot
- Nov 14th, 2024 9:25 pm
T2 Biosystems Announces Third Quarter 2024 Financial Results
- Nov 14th, 2024 9:05 pm
T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024
- Nov 5th, 2024 1:00 pm
Q3 2024 T2 Biosystems Inc Earnings Call
- Oct 11th, 2024 11:19 am
CAH Stock May Gain Following the Distribution Deal With T2 Biosystems
- Oct 9th, 2024 4:26 pm
T2 Biosystems to Host Business Update Call on October 10, 2024
- Oct 8th, 2024 8:05 pm
T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform
- Oct 8th, 2024 1:00 pm
T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
- Oct 7th, 2024 1:05 pm
T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results
- Oct 7th, 2024 1:00 pm
T2 Biosystems Highlights New Article Published in The Lancet: Changing the Culture of Blood Culture
- Sep 23rd, 2024 1:00 pm
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
- Sep 20th, 2024 1:00 pm
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients
- Sep 16th, 2024 1:00 pm
T2 Biosystems Provides Updates on its New Product Development Pipeline Progress
- Sep 9th, 2024 1:00 pm
T2 Biosystems to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- Aug 27th, 2024 8:05 pm
Scroll